All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Lipocalins are a family of extracellular proteins that can bind small hydrophobic ligands by means of a highly conserved β-barrel tertiary structure \[[@pone.0234857.ref001]\]. This protein family shows moonlighting properties and a wide functional diversity \[[@pone.0234857.ref002]\]. Only a few Lipocalins are expressed within the nervous system: Apolipoprotein D (ApoD), mainly in oligodendrocytes and Schwann cells and in astrocytes; Lipocalin-type prostaglandin D synthase (Ptgds), in oligodendrocytes; or Lipocalin 2 (Lcn2), expressed by reactive astrocytes \[[@pone.0234857.ref001],[@pone.0234857.ref003]\]. In addition to classical transcriptional control, we have recently reported that Lipocalins have a remarkable variability in 5' UTR-dependent translation efficiency, which explains differences in global protein abundance depending on their evolutionary history \[[@pone.0234857.ref004]\]. These differences in post-transcriptional regulation set apart a group of mammalian Lipocalins, where ApoD stands as the earliest diverging chordate protein according to a congruent molecular phylogeny based on primary sequence and gene architecture \[[@pone.0234857.ref005]\].

ApoD gene is expressed in several mammalian tissues, and the protein was first detected complexed to blood circulating lipoproteins. However, the nervous system is a prominent organ of expression, particularly in rodents \[reviewed by [@pone.0234857.ref006], [@pone.0234857.ref007]\]. Particularly intriguing is the fact that ApoD is one of the few genes consistently over-expressed in the aging brain of all vertebrate species tested so far \[[@pone.0234857.ref008]\]. Moreover, ApoD expression is boosted in an amazingly wide array of neurodegenerative and psychiatric diseases of diverse etiology, including schizophrenia and bipolar disorder \[[@pone.0234857.ref009]\], Alzheimer´s disease \[[@pone.0234857.ref010]\], demyelinating diseases like Multiple Sclerosis \[[@pone.0234857.ref011]\] or lysosomal storage diseases, like Niemann Pick type C disease \[[@pone.0234857.ref012]\]. Oxidative stress appears clearly as a common factor for brain aging and diseases of such varied etiologies. The mouse, as model organism, has yielded a wealth of knowledge about functions of this atypical apolipoprotein: it delays brain aging \[[@pone.0234857.ref013]\], promotes longevity and dopaminergic neuron survival under oxidative stress conditions \[[@pone.0234857.ref014],[@pone.0234857.ref015]\], and controls myelin phagocytosis and restrains inflammation after peripheral nerve injury, thus accelerating recovery \[[@pone.0234857.ref016],[@pone.0234857.ref017]\]. Finally, ApoD is required for myelin compaction during normal development \[[@pone.0234857.ref018]\]. How are all these functions coordinated? What are the mechanism controlling the upregulation of ApoD upon a neural insult due to trauma, exposure to exogenous toxics, or a wide array of neurodegenerative processes?

The influence of ApoD on the transcriptome response to Paraquat-induced oxidative stress has been characterized in the cerebellum \[[@pone.0234857.ref019]\], one of the brain regions particularly vulnerable to this insult \[[@pone.0234857.ref020]\]. On the other hand, ApoD expression is transcriptionally regulated by the JNK pathway in human astrocytoma cells upon oxidative stress \[[@pone.0234857.ref015]\], and by the MEK/ERK pathway in mouse fibroblasts (NIH/3T3 cells) upon growth arrest \[[@pone.0234857.ref021]\]. However, other layers of ApoD expression control have not been explored.

The postranscriptional regulatory control of gene expression by upstream untranslated regions (5' UTR) of mature mRNAs has gained attention in recent years \[reviewed by [@pone.0234857.ref022], [@pone.0234857.ref023]\]. They are key components of the post-transcriptional regulation due to their impact on translation efficiency. 5' UTR features such as length, G+C content, secondary structure, as well as the presence of particular sequence motifs have been demonstrated to impact on gene translation levels \[[@pone.0234857.ref024],[@pone.0234857.ref025]\].

In this work, we study both *in silico* and experimentally the role of mRNA 5' UTR sequences and gene promoter regions on the regulation of mouse Lipocalin ApoD gene expression in different tissues, developmental stages and physiological conditions.

Methods {#sec002}
=======

Computational analyses {#sec003}
----------------------

Mammalian ApoD 5' UTR sequences were obtained from the AceView database \[[@pone.0234857.ref026]\]. Only annotated transcripts containing an ApoD coding sequence (CDS) coincident with NCBI Reference Sequence (RefSeq Database) were selected. Nucleotide sequences obtained from AceView were confirmed in ASPIcDB \[[@pone.0234857.ref027]\], which also allowed including alternative transcripts.

UTR regions were analyzed with EMBOSS Infoseq, Dreg and Getorf tools \[[@pone.0234857.ref028]\]. Repetitive motifs were located with Repeatmasker (<http://repeatmasker.org>). The RNAshape algorithm (<http://bibiserv.techfak.uni-bielefeld.de/rnashapes>) \[[@pone.0234857.ref029]\] was employed to predict the minimal folding energy (MFE) and the suboptimal structures of ApoD 5' UTRs, selecting a range of MFE + 5 Kcal/mol for the suboptimal structures. We evaluated structural similarities of the predicted alternative UTR structures with RNAforester (<http://bibiserv2.cebitec.uni-bielefeld.de/rnaforester>) \[[@pone.0234857.ref030]\], and the structures were studied with PseudoViewer \[[@pone.0234857.ref031]\]. To predict regulatory motifs in 5' UTR we used Predict a motif \[[@pone.0234857.ref032]\], the RNAalifold algorithm \[[@pone.0234857.ref033]\] and RNAstructure (v6.1) \[[@pone.0234857.ref034]\].

AceView database annotations were used to map exon-intron organization. 5' UTR genomic regions were additionally examined with ExonScan \[[@pone.0234857.ref035]\] to predict potential exons. The presence and category of constitutive, alternative or cryptic splicing sites flanking exons were predicted with ASSP \[[@pone.0234857.ref036]\].

Promoter regions were identified as those annotated by the ENCODE project \[[@pone.0234857.ref037]\], and predicted by the Genomatix database (<http://www.genomatix.de>). Promoter predictions were carried out by NNPP (<http://www.fruitfly.org/seq_tools/promoter.html>) \[[@pone.0234857.ref038]\], FPROM (<http://www.softberry.com/berry.phtml?topic=fprom&group=programs&subgroup=promoter>) \[[@pone.0234857.ref039]\], YAPP (<http://www.bioinformatics.org/yapp/cgi-bin/yapp.cgi>) \[[@pone.0234857.ref040]\] and Promoter 2.0 (<http://www.cbs.dtu.dk/services/Promoter/>) \[[@pone.0234857.ref041]\] algorithms. Promoter predictions and ApoD gene structure were visualized with the IGV browser V2.5.3 (<https://software.broadinstitute.org/software/igv>) \[[@pone.0234857.ref042]\]. To find internal duplications in the 5' upstream genomic regions of human and mouse ApoD we used PLALIGN \[[@pone.0234857.ref043]\]. In order to find possible regulatory sites in ApoD promoter regions, we performed a computational sequence search for potential transcription factor binding sites using ModelInspector (<http://www.genomatix.de>) \[[@pone.0234857.ref044]\].

Animals and cell cultures {#sec004}
-------------------------

C57BL/6J mice (RRID:IMSR_JAX:000664) were maintained in positive pressure-ventilated racks at 25±1°C with 12 h light/dark cycle, fed ad libitum with standard rodent pellet diet (Global Diet 2014; Harlan Inc., Indianapolis, IN, USA), and allowed free access to filtered and UV-irradiated water. Mice were normally housed in groups of 3--4 animals/cage, but were kept individually caged for the experimental treatment. The University of Valladolid Animal Care and Use Committee following the regulations of the Care and the Use of Mammals in Research (European Commission Directive 86/609/CEE, Spanish Royal Decree ECC/566/2015) approved experimental procedures (CEEBA Univ. Valladolid, project \#8702359). For oxidative stress treatment, six month old male mice were randomly subject to either a single intraperitoneal injection of Paraquat (PQ, Sigma; 30 mg/kg) in 200 μl sterile saline (experimental group, n = 6), or a similar volume of sterile saline (control group, n = 4). Six hours after injections, mice were euthanized with CO~2~ and their cerebella immediately removed and frozen. No animal suffering was observed during the short treatment period. Other tissues (adipose, heart, colon and lung) were extracted from control mice. Whole brain or cerebellum were extracted from embryos (E13.5) or postnatal control mice (P10) respectively (n = 3/stage), euthanized with CO~2~ and their tissues immediately frozen.

The mouse astrocytic cell line IMA2.1 (RRID:CVCL_X370) was grown in Dulbecco Modified Eagle´s Medium (DMEM) without phenol red, with 5% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, and 0.25 μg/ml amphoterycin, with subculture cycles every 48 hours when they reach 80% confluence. Oxidative stress treatment of cells (0.5 or 1 mM PQ) was carried out in low serum media (0.2% FBS; all other components as above).

Immunocytochemistry {#sec005}
-------------------

Cultured IMA2.1 astrocytes attached to poly-L-lysine (Sigma)-treated coverslips were fixed with 4% formaldehyde, washed in phosphate buffered saline (PBS), blocked and permeabilized with Tween-20 (0.1%) and 1% non-immune calf serum. We used a goat polyclonal anti-mouse ApoD (SC Biotechnology) as primary antibody, and Alexa 488-conjugated donkey anti-goat IgG serum (Jackson Immunoresearch) as secondary antibody. Coverslips were mounted with EverBrite^™^-DAPI Mounting medium, and sealed with CoverGrip^™^ sealant (Biotium). Cells were visualized and photographed with an Eclipse 90i (Nikon) fluorescence microscope equipped with a DS-Ri1 (Nikon) digital camera, and images were processed and analysed with the Fiji Program.

Genomic PCR, RT-PCR and Real-time quantitative PCR {#sec006}
--------------------------------------------------

Mouse tissues used for mRNA expression studies were stored at -80°C, and RNA was extracted using QIAzol Lysis Reagent (Qiagen). RNA concentration was measured with a Nanodrop spectrophotometer, and its quality assessed by 260/230 and 260/280 spectrophotometric ratios measured with a spectrophotometer and by agarose electrophoresis. RNA obtained from individual samples of the same tissue or experimental condition were pooled in equimolar amounts to be reversed transcribed. Following DNAse treatment, 500 ng of total RNA were reverse-transcribed with PrimeScript (Takara Bio Inc., Otsu, Japan) using Oligo-dT primers and random hexamers. Genomic DNA absence was also confirmed by RT(-) amplifications. Genomic DNA was obtained from a mouse brain after RNA purification following the QIAzol (Qiagen) protocol, and its concentration was measured with Nanodrop.

Mouse cDNA was used as a template for standard RT-PCR using GoTaq^®^ (Promega), or quantitative real-time RT-PCR (RT-qPCR) using SybrGreen (SYBR^®^ Premix Ex Taq^™^ kit, Takara). Genomic DNA was used for testing 5' UTR primers, and for amplification and cloning of ApoD promoters. The primers used in PCR amplifications are shown in [Table 1](#pone.0234857.t001){ref-type="table"}.
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###### PCR primers used in this work.

![](pone.0234857.t001){#pone.0234857.t001g}

  Experiment                 Primer    Sequence
  -------------------------- --------- ------------------------------
  Genomic PCR; RT-PCR        pU1-F     `AGGGGACAGACACAGCATCCCA`
  Genomic PCR; RT-PCR        pU2-F     `GGAGGATTCTGGGTGGAAACTTCAG`
  Genomic PCR; RT-PCR/qPCR   pU3-F     `AGTTGGAGCTTGCACTTGGGGT`
  Genomic PCR; RT-PCR/qPCR   pU4-F     `CCTCGGTGCTGAGGAGAATTCCA`
  Genomic PCR; RT-PCR/qPCR   pU2-R     `AGCCTTCAGTTGGTGCTCACTGT`
  Genomic PCR; RT-PCR/qPCR   CDS-R     `CGTGGCCAGGAACATCAGCATG`
  RT-PCR                     1-F       `GAAGCCAAACAGAGCAACG`
  RT-PCR                     1-R       `AGCCTCACAGACTGATTCAGGG`
  RT-PCR                     2-R       `AGCACTTCGATGTTTCCGTTCTCC`
  RT-PCR                     3-R       `AGCTTGGCTGGCTCTGAGACG`
  RT-PCR                     4-R       `TGTTTCTGGAGGGAGATAAGGA`
  Promoter Cloning           PROMA-F   `GGAACGTTCAGCAGATCACTT`
  Promoter Cloning           PROMA-R   `GAGAGCGAGAGCGAGAGAGAAAGAC`
  Promoter Cloning           PROMB-F   `TGTTATTGGAACCCGTTTTCAGGTG`
  Promoter Cloning           PROMB-R   `ACCTCTTTTCAAGCATCTCTTGTTGG`
  RT-qPCR                    Rpl18-F   `TTCCGTCTTTCCGGACCT`
  RT-qPCR                    Rpl18-R   `TCGGCTCATGAACAACCTCT`

The mRNA transcription levels were assessed with the ΔΔCT method \[[@pone.0234857.ref045]\] using normalization to the Rpl18 gene for each condition. Five technical replicas were performed with each sample set. Bacterial plasmid DNA was used as negative template control. Statistically significant differences of gene transcriptional changes were evaluated with a Mann-Whitney U-test \[[@pone.0234857.ref046]\] using ΔCT of each replica (calculated by subtracting the average CT of the reference gene for each sample).

Promoter cloning and gene expression evaluation {#sec007}
-----------------------------------------------

The two mouse ApoD genomic regions showing sequence conservation with human ApoD sequences ([Fig 5](#pone.0234857.g005){ref-type="fig"}) were PCR-amplified and cloned in the pCR^®^II-TOPO^®^ vector (Invitrogen), and confirmed by DNA sequencing. These proposed promoter regions (α and β) were then digested with restriction enzymes and directionally cloned in the pGL4.10\[*luc2*\] reporter vector (Promega). Astrocyte IMA2.1 cells were Lipofectamine (Invitrogen)-transfected with the mouse ApoD promoter (α or β)-pGL4.10\[*luc2*\] plasmids. The promoter-driven expression of Luciferase was tested with the Dual-Luciferase^®^ Reporter Assay System (Promega) following the manufacturer's specifications. Briefly, cells were transfected with each luciferase reporter construct and a Renilla expression vector at a 10:1 ratio. After an 18 h post-transfection period, cells were incubated for 2 h with Low Serum media (control conditions) or PQ (0.5 or 1 mM) in Low Serum media. Luminescence was then measured in cell lysates with a BMG LABTECH 96 microplate luminometer. Experiments were performed in triplicates. Promoter activities were expressed relative to Renilla activity. PQ-dependent activity was normalized to values obtained in control conditions.

Statistical analysis {#sec008}
--------------------

Statistical analyses were performed with SPSS v.19 (IBM) and SigmaPlot v.11.0 (Systat). A *p* value \< 0.05 was considered as threshold for significant changes and marked with asterisks in figures. The tests used for each experiment are described in figure legends.

Results {#sec009}
=======

ApoD 5' UTR properties evidence selective pressure and tight translational control {#sec010}
----------------------------------------------------------------------------------

The particular position of ApoD as an early-diverging Lipocalin within chordate evolution \[[@pone.0234857.ref005]\], its functional diversity and apparent pleiotropy (influencing a wide array of processes, from metabolic traits to myelin management, neurodegeneration or aging progression), together with its tissue and stimulus-specific expression, triggered the present analysis of regulatory regions previously unexplored for the mouse ApoD gene.

First we focus on the *in silico* analysis of ApoD 5' UTR in mammals, as a potential source of post-transcriptional variations in its gene expression control. A comparison of the 5' UTR sequences of ApoD mRNAs of several mammalian orders (using the transcripts annotated as RefSeq) shows a 78% identity \[[@pone.0234857.ref004]\], a value comparable to those obtained when comparing the 3^rd^ position of codons in the CDS of the same set of transcripts. This strong sequence conservation is apparent in multiple sequence alignment of sequences diverging up to 120 My ago ([Fig 1](#pone.0234857.g001){ref-type="fig"}).

![Evolutionary conservation of ApoD 5' UTR in mammals.\
Multiple sequence alignment of the RefSeq 5' UTRs of several mammalian species. Nucleotide sequence identity across all taxa are highlighted in black. A conserved TATA box is marked by a square, and the beginning of the CDS is pointed by an arrow. Hsap: Homo sapiens (primates); Sbol: Saimiri boliviensis (primates); Mmur: Microcebus murinus (primates); Mus musculus (rodentia); Pvam: Pteropus vampyrus (chiroptera); Umar: Ursus maritimus (carnivora); Sscr: Sus scrofa (artiodactyla).](pone.0234857.g001){#pone.0234857.g001}

This high sequence conservation for an early-diverging chordate Lipocalin suggests the existence of strong selective pressure on ApoD 5' UTR sequence and, therefore, on its regulatory role in ApoD expression.

Properties of 5' UTRs that are suitable to promote gene translation are a short sequence length, a reduced G+C content, a negative minimum folding energy (MFE) for their secondary structure, and the absence of unstructured (linear) regulatory elements such as upstream initiation codons (uAUG) or of upstream open reading frames (uORF), and \[[@pone.0234857.ref025],[@pone.0234857.ref047],[@pone.0234857.ref048],[@pone.0234857.ref049]\]. When analyzing these properties in human and mouse ApoD 5' UTRs, we find that although they show lengths and G+C content values similar to their average in both species, the presence of uAUGs and uORFs \[[@pone.0234857.ref004]\] suggests a tight translational control of this gene.

Alternative 5' UTRs in mouse ApoD are differentially expressed depending on tissue or physiological conditions {#sec011}
--------------------------------------------------------------------------------------------------------------

The accumulated knowledge on ApoD function in the mouse model, particularly relevant to understand its role in nervous system maintenance and resistance to neurodegeneration, led us to experimentally test the role of mouse ApoD 5' UTR and to analyze its regulatory potential.

An analysis of the genomic sequence of the 5' UTR region of human and mouse ApoD reveals that it is composed of several exons, an arrangement found in all mammals studied so far \[[@pone.0234857.ref004]\]. [Fig 2A](#pone.0234857.g002){ref-type="fig"} shows the exon arrangement of the mouse ApoD gene, where four exon fragments contribute to the 5' UTR as predicted by ExonScan ([Fig 2B](#pone.0234857.g002){ref-type="fig"}) and ASSP ([Fig 2C](#pone.0234857.g002){ref-type="fig"}). These exons contribute totally or partially to the set of 5' UTR variants ([Fig 2D](#pone.0234857.g002){ref-type="fig"}) found by *in silico* analysis (AceView and ASPIcDB). Such a set of five variants is the largest number of alternative 5' UTRs predicted for a mammalian Lipocalin gene \[[@pone.0234857.ref004]\]. The presence of different numbers and fragments of 5' UTR exons in the variants suggests RNA splicing as a mechanism to generate such diversity. Predicted splice sites are pointed by arrows in [Fig 2A](#pone.0234857.g002){ref-type="fig"}. [Fig 2E](#pone.0234857.g002){ref-type="fig"} shows several properties of each variant, all of which categorize them as "low translation efficiency" 5' UTRs, based on the classification and regression tree (CART, class I) method \[[@pone.0234857.ref050]\]. This circumstance also suggests that different cell types or physiological states of a given cell could influence the regulatory impact of ApoD 5' UTR depending on the variant expressed.

![Bioinformatic analyses of mouse ApoD 5' UTR region.\
A) Predicted exonic structure of mouse ApoD 5' UTR region. Arrows point to predicted splice sites. Exon boundaries are marked by numbers in relation to the ORF. B) ExonScan prediction of potential exonic 5' UTR sequences. 5'SS (donor) and 3'SS (acceptor) indicate probabilities of splice sites in comparison to decoy at both ends. ESE (exonic splicing enhancers) values are the estimated odd of a given string being an exon relative to being an intron. ESS (exonic splicing silencers) values are the estimated odd of being a pseudoexon in contrast to being an exon. Intronic GGG takes a small constant value when located 100--40 bases upstream or 10--70 bases downstream a candidate exon. Total refers to the sum of scores for every candidate exon. C) ASSP classification and estimated probability of predicted exonic 5' UTR sequences. Both ExonScan and ASSP predictions are very similar. D) Exon composition of the transcriptional variants of mouse ApoD 5' UTR annotated in AceView database. E) Primary and secondary structure properties of mouse ApoD 5' UTR variants, including estimated minimal folding energy (MFE), number of upstream AUG codon (uAUG) and class resulting from the classification and regression tree (CART) method.](pone.0234857.g002){#pone.0234857.g002}

To confirm experimentally the expression of the predicted 5' UTR mouse variants we used RT-PCR amplifications with a combination of oligonucleotide pairs ([Fig 3A](#pone.0234857.g003){ref-type="fig"} and [Table 1](#pone.0234857.t001){ref-type="table"}) that help us to reveal the different 5' UTR variants. We first checked that each oligonucleotide pair amplifies the expected size product from genomic DNA (not shown). We then chose cDNAs from heart, colon, lung, adipose tissue, and cerebellum as templates for amplification. To test for the existence of developmental regulation of ApoD expression within the nervous system, we compared embryonic day 13.5 brain, postnatal day 10 cerebellum, and 6 months old cerebellum. Finally, we also tested whether oxidative stress can modulate 5' UTR variants expression by comparing adult cerebellum of control mice with those treated for 6 h with Paraquat (PQ) as an oxidative stress generator. Cerebellum was selected because of its reported expression of ApoD and its sensitivity to PQ \[[@pone.0234857.ref019]\].

![Experimental demonstration of tissue, time and condition-dependent expression of mouse ApoD 5' UTR variants.\
A) Schematic diagram of 5' UTR and CDS exons of mouse ApoD to map the location and direction of primers used in RT-PCR and RT-qPCR experiments. B) Control RT-PCR amplifications of mouse ApoD CDS in several tissues. Adip: adipose tissue; Cb: cerebellum; P10: postnatal day 10; 6M: six months old; E13.5 Br: brain of 13.5 days mouse embryo; PQ: Paraquat, 6 h in vivo treatment; (-): negative control template. Biological replicas used in these experiments are detailed in the methods section. C-F) PCR amplification products of mouse ApoD 5' UTR variants. Primer combination and/or band size help us to discriminate among variants. G-H) Real time RT-qPCR expression levels of variants B and E demonstrate brain specificity of variant B and PQ induction of variant E. Average fold change and standard deviation of five technical replicas are represented. Significance was assessed on the original ΔCT values of each replica with a Mann-Whitney U-test. I) RT-PCR demonstration of full transcription of ApoD mRNA containing the complete CDS with 5' UTR Variant E in cerebellum.](pone.0234857.g003){#pone.0234857.g003}

First we tested by RT-PCR amplifications that ApoD coding sequence is detected in all tissues and conditions studied (CDS; [Fig 3B](#pone.0234857.g003){ref-type="fig"}). Some 5' UTR variants are amplified more prominently than others when comparing with the CDS expression in each tissue or condition ([Fig 3C--3F](#pone.0234857.g003){ref-type="fig"}). The fragments amplified from variants A or C appear to be generally expressed in the tissues studied ([Fig 3C and 3D](#pone.0234857.g003){ref-type="fig"}). However, variants B, D, and E show a clear nervous system expression specificity, with minor or no presence in the other tissues tested ([Fig 3C--3F](#pone.0234857.g003){ref-type="fig"}). Finally, variant E shows an interesting pattern, as it appears differentially expressed in the oxidative stress-challenged cerebellum ([Fig 3F](#pone.0234857.g003){ref-type="fig"}).

Since the results above were obtained from standard RT-PCR evaluated after 35 cycles of amplification, we wanted to confirm our results using real-time RT-qPCR. Template concentration was evaluated by using the ΔΔCT method \[[@pone.0234857.ref045]\] and normalization with the Rpl18 gene. RT-qPCR confirms that variant B is more abundant in cerebellum than heart ([Fig 3G](#pone.0234857.g003){ref-type="fig"}), and variant E is 3-fold overexpressed in the Paraquat-treated cerebellum ([Fig 3H](#pone.0234857.g003){ref-type="fig"}). Since variant E has such a condition-specific expression, we wanted to confirm whether it forms part of a fully translatable mRNA containing the full ApoD CDS (all previous amplifications were carried out with a reverse primer located at the 5' end of the CDS; Primer CDS-R, [Fig 3A](#pone.0234857.g003){ref-type="fig"}). Using a forward primer in the first CDS exon of ApoD gene and reverse primers in different locations of ApoD CDS (coding exons 2, 3, and 4), and a negative control primer located in the first intron interrupting the CDS (primer 1-R), we were able to amplify the expected band sizes ([Fig 3I](#pone.0234857.g003){ref-type="fig"}).

In summary, our experiments demonstrate the existence of alternative 5' UTRs in the ApoD gene that have differential tissue or condition-dependent expression. Three of the variants are enriched particularly in the nervous system, with expression ranging from embryonic development to adulthood, and one of them (variant E) shows a remarkable specific induction upon PQ treatment.

ApoD 5' UTR secondary structure predictions reveal varied degrees of protein expression control {#sec012}
-----------------------------------------------------------------------------------------------

The secondary structure of UTR regions is known to influence their role in gene expression regulation \[[@pone.0234857.ref025]\]. The 5' UTR folding can be predicted based on calculations of its free energy with the RNAshape algorithm \[[@pone.0234857.ref029]\], resulting in a minimal folding energy (MFE) structure as well as suboptimal structures predicted within a certain range of free energy.

The interesting functional implications of 5' UTR variants of mouse ApoD led us to study the MFE and MFE+5 Kcal/mol suboptimal structures in all variants described above. The 5' UTR modeled secondary structures of Lipocalins show limited deviations from their MFE structures \[[@pone.0234857.ref004]\], suggesting that MFE is representative of the native structure. This result also points to structural elements predicted to be evolutionarily conserved and potentially important for gene expression regulation. [Fig 4A](#pone.0234857.g004){ref-type="fig"} displays the 5' UTR MFE structures of four mammalian orthologs of mouse ApoD. Highlighted in color we show several secondary structure motifs predicted by Predict a motif \[[@pone.0234857.ref032]\]. These motifs are well conserved in primates (*Homo sapiens* and *Saimiri boliviensis*), cow and pig sequences (*Bos taurus* and *Sus scrofa*), while the mouse orthologous 5' UTR preserves a single structural motif. [Fig 4B](#pone.0234857.g004){ref-type="fig"} shows the mouse ApoD RefSeq 5' UTR, highlighting in red its strong conservation with predicted suboptimal structures, making the MFE structure a good predictor of the native 5' UTR structure. Similar results are achieved when 5' UTR foldings are predicted with RNAalifold \[[@pone.0234857.ref033]\] and RNAstructure \[[@pone.0234857.ref034]\] (not shown).

![Secondary structure prediction of ApoD 5' UTRs.\
A) Secondary structure with minimal folding energy (MFE) predicted by the RNAshape algorithm for the RefSeq 5' UTRs of several mammalian species. Colored motifs predicted for the human 5' UTR are conserved in other mammalian sequences. B) MFE secondary structure of the ApoD mouse RefSeq 5' UTR with red-colored regions preserved in suboptimal structures (in the interval MFE + 5Kcal/mol). C) MFE secondary structure predictions of the five 5' UTR alternative variants of mouse ApoD. Blue and light-blue regions highlight predicted upstream open reading frames (uORF), while arrows point to predicted upstream initiation codons (uAUG).](pone.0234857.g004){#pone.0234857.g004}

Next we analyzed the secondary structures predicted for mouse ApoD alternative 5' UTRs. They can be grouped in three categories in agreement with their lengths: variants A-B, variants C-D and the unique variant E. Variant A shows the highest free energy (-42 Kcal/mol; [Fig 2E](#pone.0234857.g002){ref-type="fig"}), close to the -30 Kcal/mol free energy limit to negatively regulate translation \[[@pone.0234857.ref051]\]. Instead, the remaining variants, with low free energies (-69 to -126 Kcal/mol), are expected to inhibit gene translation more efficiently, thus representing a mechanism of restraint for ApoD protein expression.

Another interesting finding is that unstructured regulatory elements such as upstream open reading frames (uORF) are predicted only in variants B-E of ApoD 5' UTRs (highlighted in blue tones in [Fig 4C](#pone.0234857.g004){ref-type="fig"}), which might underlie the different degree of expression observed in several mouse tissues ([Fig 3C--3F](#pone.0234857.g003){ref-type="fig"}). Variant A shows a global expression in the tissues explored, coincident with its high MFE value and the lack of uORFs, both properties implicated in negative regulation of translation. The localization of uORFs, and specially their uAUGs (arrows in [Fig 4C](#pone.0234857.g004){ref-type="fig"}), in predicted hairpin structures of variants B-E suggests a tight translational control that could explain the restricted expression in different tissues and/or physiological conditions demonstrated above.

Two promoter regions, differentially regulated by oxidative stress, drive the expression of mouse ApoD {#sec013}
------------------------------------------------------------------------------------------------------

The regulation of ApoD gene expression has been studied in detail by analyzing experimentally the promoter region of human ApoD \[[@pone.0234857.ref021],[@pone.0234857.ref052],[@pone.0234857.ref053]\]. A region of \~2 kb upstream of human ApoD exon 1 was reported to contain regulatory elements, such as an alternating purine-pyrimidine stretch and serum-responsive elements (SRE), that regulate ApoD expression upon a metabolic insult (serum deprivation) \[[@pone.0234857.ref052]\].

However, a promoter analysis of the mouse ApoD gene has not been reported so far. Using the sequence of the \~7 kb stretching from the 5'-flanking region of the human promoter region studied by Do Carmo et al. \[[@pone.0234857.ref052]\], we BLAST searched the 5' upstream genomic region of the mouse ApoD gene. Interestingly, two long sections showed significant sequence similarity (labeled 1 & 2 in the Dot plot shown in [Fig 5A](#pone.0234857.g005){ref-type="fig"}) between the human and mouse 5' upstream regions. Section 1 corresponds to part of the human promoter region and the first exon, and matches the first three 5' UTR exons of mouse ApoD. Section 2 lies in an intronic region between 5' UTR exons of both human and murine ApoD. Because of the unexpected similarity found in an intronic sequence, we first confirmed *in silico* that this region does not relate in any strand or frame to a different gene. We then searched and compared the predicted transcription initiation sites in the human gene ([Fig 5B](#pone.0234857.g005){ref-type="fig"}) with those of the mouse genomic sequence under study ([Fig 5C](#pone.0234857.g005){ref-type="fig"}). Three putative initiation sites were predicted by NNPP in the genomic 5'-flanking region of mouse ApoD gene, but only one canonical TATA box was identified in site \#2 (black arrow in [Fig 5C](#pone.0234857.g005){ref-type="fig"}).

![Promoter predictions for the mouse ApoD gene (I).\
A) Dot matrix representation of a pairwise alignment of human vs. mouse ApoD upstream gene sequences, covering approximately 6000 bp upstream of the CDS start site and comprising 5' UTR and the reported/predicted human/mouse promoter regions (colored rectangles). Black and striped boxes indicate ExonScan predicted 5' UTR exons. Region 1 matches a big portion of the reported human promoter and maps to the first mouse 5' UTR exons. Region 2 locates in the 5' UTR long intron in both genes. Only diagonals with p\<0.001 are shown. B) The table shows three potential initiation transcription sites in human ApoD locus (black arrows in the diagram) detected by a neural network prediction algorithm. The third one lies within the first 5' UTR exon. Predicted TATA boxes appear underlined. C) Three potential transcription initiation sites are detected in mouse ApoD locus. The second one lies in the 5' UTR, in a region similar to the reported human promoter, and contains a predicted TATA box (black arrow in the diagram). Two other initiation sites (white arrows) do not contain a TATA box, including the site located in the large intron.](pone.0234857.g005){#pone.0234857.g005}

Two initiation sites locate in front of the 5' UTR exons that could correspond to a canonical (α) promoter homologous to the one that has been analyzed for human ApoD. Another potential site is predicted with high score in the intronic sequence downstream 5' UTR exons 1--3. These predictions were supported by other algorithms (YAPP, FPROM and Promoter 2.0; [Fig 6A](#pone.0234857.g006){ref-type="fig"}) \[[@pone.0234857.ref039],[@pone.0234857.ref040],[@pone.0234857.ref041]\], and suggest that this region might be functioning as an alternative (β) promoter for the mouse ApoD gene ([Fig 6B](#pone.0234857.g006){ref-type="fig"}), located upstream of 5' UTR exon 4 (the one fully present in variant E). Likewise, the Genomatix portal predicts two promoter regions within α and β fragments (GXP_419688 and GXP_3072215; [Fig 6A](#pone.0234857.g006){ref-type="fig"}). Using these sequence regions, the ModelInspector algorithm \[[@pone.0234857.ref054]\] predicts a series of binding sites that appear enriched for a number of transcription factors ([Fig 6C](#pone.0234857.g006){ref-type="fig"}). Promoter α is enriched for AP1 and NFκB, which have been demonstrated to regulate ApoD transcription in human cells \[[@pone.0234857.ref055]\]. Similarly, promoter α shows binding sites for NFAT, which forms a cooperative complex with AP1 and is involved in nervous system development \[[@pone.0234857.ref056]\], and for CBF-α, which has been found to bind the human ApoD promoter \[[@pone.0234857.ref021]\]. However, promoter β shows a very different pattern of transcription factor binding sites, being CEBP the most common. CEBP is involved in cell proliferation, growth and differentiation, particularly in the nervous system \[[@pone.0234857.ref057]\]. Other factors like SMAD, FKHD and SP1 are also predicted to regulate ApoD by binding promoter β, though with a lower number of predicted binding sites. An interesting finding is SP1, which is known to bind GC-rich promoter regions and activate transcription in the absence of TATA box or initiator sites \[[@pone.0234857.ref058]\], as it is the case in promoter β ([Fig 6C](#pone.0234857.g006){ref-type="fig"}).

![Promoter predictions for the mouse ApoD gene (II).\
A) Bioinformatic predictions of promoter elements in the upstream 5' region of the mouse ApoD coding sequence. Information obtained from the NNPP, FPROM, YAPP and PROMOTER2_0 are visualized with the Integrated Genomics Viewer (IGV). Three high score NNPP-predicted and two FPROM-predicted initiation sites are noted by red arrows. Blue arrow points to the TATA box-containing initiation site in Promoter I (canonical α), as predicted by YAPP. Green arrow points to predicted initiator (INR) and downstream promoter element (DPE) in Promoter II (alternative β) optimally spaced (20--30 bp) for transcription initiation upstream of the 5' UTR exon 4. Purple bars delimit the promoter regions identified by Genomatix. B) Schematic representation of the mouse ApoD locus drawn at the same scale as panel A. Promoter fragments α (2 Kb) and β (3 Kb) cloned for Luciferase assays are represented. They include the regions identified by Genomatix (GXP) as Promoter I and Promoter II respectively. C) Transcription factor binding sites predicted by ModelInspector are mapped onto the GXP promoter regions (enlarged scale). NFKB (yellow triangles), NFAT (red triangles), CBFα (green diamonds), AP1 (blue rectangle), CEBP (green ovals), SP1 (orange diamond). Binding of multiple factors is predicted at various locations.](pone.0234857.g006){#pone.0234857.g006}

We thus set to experimentally test the expression capabilities of promoter fragments α and β ([Fig 6B](#pone.0234857.g006){ref-type="fig"}) using a Luciferase reporter assay in the IMA2.1 mouse astrocytic cell line. These cells show a low vesicular ApoD expression by immunolabeling under control condition, which increases when challenged with PQ ([Fig 7A and 7B](#pone.0234857.g007){ref-type="fig"}). This expression regulation is similar to that found in primary mouse astrocytes \[[@pone.0234857.ref015],[@pone.0234857.ref059]\] and in the mouse brain upon similar oxidative stress conditions \[[@pone.0234857.ref014],[@pone.0234857.ref019]\]. The Luciferase expression driven by promoter α is higher than that of promoter β under control conditions ([Fig 7C](#pone.0234857.g007){ref-type="fig"}). Promoter α region drives an enhanced (\~1.5-fold) Luciferase activity in response to PQ ([Fig 7D](#pone.0234857.g007){ref-type="fig"}), as expected for the reported stress-regulated expression of ApoD, but this response was dampened with increasing PQ concentration. However, PQ triggers in promoter β a 2-fold increase in expression that keeps rising (3-fold) with a higher dose of PQ. These results demonstrate that the promoter β genomic region has the capability to promote expression proportionally to oxidative stress levels, and thus might function as an alternative promoter for ApoD expression in mouse astrocytes. Since this genomic region lies right upstream of the 5' UTR exon 4 sequence that constitutes variant E of ApoD mRNA, its promoter activity could be related to the OS-dependent expression of the 5' UTR variant E.

![Canonical and alternative mouse ApoD promoter-driven expression in astrocytes upon PQ treatment.\
A) Representative images of differential interference contrast (upper panels) and fluorescence ApoD immunodetection (lower panels) in IMA2.1 mouse astrocyte cells under control and PQ-induced oxidative stress conditions. ApoD expression increases in the astrocytic cell line upon oxidative stress. Calibration bars: 20 μm. B) Mouse ApoD expression evaluated by immunofluorescence signal intensity in IMA2.1 cells in control (48 cells) and PQ (60 cells) conditions. Significance was assessed by unpaired Student's t-test. C-D) Luciferase expression assays in IMA2.1 co-transfected cells, normalized to control. Normalized average values and standard deviation are represented. Expression driven by the Prom-α fragment is constitutively higher than that of Prom-β. Significance was assessed by a Welch's unequal variances t-test. (C). An oxidative stress insult with PQ increases Luciferase activity levels through both promoter constructs, but the highest response at the concentrations tested is driven by Prom-β. Significance was assessed by a two-way ANOVA with Holm-Sidak post-hoc correction. (D).](pone.0234857.g007){#pone.0234857.g007}

Discussion {#sec014}
==========

Apolipoprotein D is one of the few Lipocalins prominently expressed in nervous system. It is characterized by diverse and unique functional traits conditioning nervous system development, maintenance through aging, and response to disease \[[@pone.0234857.ref013],[@pone.0234857.ref014],[@pone.0234857.ref015],[@pone.0234857.ref016],[@pone.0234857.ref017],[@pone.0234857.ref018],[@pone.0234857.ref059],[@pone.0234857.ref060],[@pone.0234857.ref061],[@pone.0234857.ref062]\]. Regulation of ApoD gene transcription by oxidative stress and metabolic stimuli has been reported, revealing ApoD as a downstream target of JNK and MEK/ERK pathways \[[@pone.0234857.ref015],[@pone.0234857.ref021]\]. However, other levels of regulation of gene expression have not been explored.

Translation efficiency has been reported to correlate to the evolutionary history in Lipocalins, mainly due to postranscriptional regulation mechanisms related to the 5' UTR \[[@pone.0234857.ref004]\]. ApoD makes a particularly attractive case for an in depth study of this region, as this gene is considered the earliest diverging member of the family in chordates \[[@pone.0234857.ref005],[@pone.0234857.ref063],[@pone.0234857.ref064]\], in contrast with the Lipocalins Ptgds and Lcn2, also expressed in the brain, that diverged from progressively more recent family branches. At the sequence level, ApoD 5' UTR shows the signs of strong selective pressure, with high conservation between mammalian orthologs (78.2%). This conservation is in the range of CDS third codon position, compared to 65,7% for Ptgds and 47,1% for Lcn2 5' UTRs \[[@pone.0234857.ref004]\]. Noteworthy, mouse ApoD stands out among mammalian Lipocalin genes for having the largest number of exons (four) in its 5' UTR, which can splice totally or partially to form up to five alternative variants. This scenario contrasts with a single exon, with two alternative 5' UTRs, in Ptgds, and one exon and single 5' UTR in Lcn2. Our results demonstrate that the potential variability derived from the ability to generate up to five mRNA species with different 5' UTRs is in fact exploited by the mouse ApoD gene. The 5' UTR variants are differentially expressed across tissues and conditions. Three variants (B, D and E) are enriched particularly in the nervous system, with expression levels varying across developmental stages. Previously unexpected but not surprising, given the biological conditions where ApoD overexpression has been reported in the nervous system, one variant (E) shows a strong induction upon oxidative stress in adult mice cerebellum. In contrast to Variant A, which does not have linear elements known to downregulate translation (uORFs and uAUGs) \[[@pone.0234857.ref025]\], Variants B to E present one or two of these elements, predicted to locate in hairpin secondary structures. This suggests that mRNAs with these 5' UTR variants exert a tight control on ApoD gene translation, explaining the tissue and physiological expression differences.

Strikingly, a comparison of the upstream regions of the human and mouse ApoD orthologs has revealed an additional layer of transcriptional regulation in the form of a functional alternative promoter located in a large 5' UTR intron of the murine gene. This Promoter β (in contrast to the canonical α) lacks typical elements such as TATA box, but instead possesses binding sites for SP1 factor, known to bind GC-rich regions and activate transcription in the absence of TATA box or other initiators \[[@pone.0234857.ref058]\]. Although Promoter β yields less gene expression than α in cultured mouse astrocytes in control conditions, incremental doses of the oxidative stress generator PQ produce a modulated increase in Promoter β activity that is not present in α-driven expression. We postulate that Promoter β might be working in association with 5' UTR variant E, as a regulatory tandem triggered by oxidative stress that works both at pre and postranscriptional levels.

The wealth of knowledge on ApoD response to brain aging, disease and injury strongly supports that ApoD gene upregulation is an endogenous mechanism of neuroprotection. In this sense, the 5' UTR variation discovered in mouse ApoD should be further explored in the human gene, given its potential role in regulating ApoD response to aging and many neurodegenerative diseases, both causally related to oxidative stress. While protein-based therapies are also possible, pharmacological manipulations of regulators upstream of ApoD endogenous expression should open new therapeutic avenues. The unexpected pattern of 5' UTR variants expression, combined with activation of alternative promoters with different transcriptional regulatory elements, brings a new layer of regulatory complexity worth exploring to understand and manipulate the neuroprotective potential of ApoD.
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Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Ganfornina et al. describe the potential role of differentially expressed APOD variants in the brain, especially in response to oxidative stress. The authors primarily utilize in silico methods for this work and assess some of their predictions using mice. The authors argue that evolutionary constraints in the 5' UTR of ApoD suggest an underlying function and show that various isoforms are in fact expressed in different tissues and under oxidative stress. They use in silico approaches to map the ApoD 5' UTR and predict its secondary structure and promoter. They conclude their study by demonstrating that oxidative stress alters the promoter used to drive expression of ApoD in cultured mouse astrocytes.

While the authors' findings are interesting, this work is largely preliminary and would necessitate the addition of functional data prior to publication to provide support for their predictions. The majority of the evidence for the author's predictions is gathered using in silico methods (Figs. 1-2, 4-6) with additional evidence representing limited confirmation of these predictions in vitro (Figs. 3, 7). The computational methodologies used by the authors are not novel and are similar to those used in the author's previous publication last year in this same journal. Thus, only the in vitro assays represent novel data that isn't readily available using online tools.

Even though the in vitro data reveal interesting findings, there are many questions remaining as to how ApoD expression is regulated. For the predicted structures, further study is needed to validate predictions (gel electrophoresis or mass spec techniques). Moreover, the authors only probed embryonic whole brain and postnatal cerebellum of mice. As the authors argue that these findings may impact knowledge on the aging brain, it would be important to test postnatal tissue including additional regions of the brain, especially those regions most affected in disease (e.g. Alzheimer's). Why is the cerebellum preferentially responsive to oxidative stress? Why did the authors choose to examine their mechanism in cultured astrocytes versus other cell types in the brain (Fig. 7)? Is ApoD regulation present in neurons or other glia subtypes? What are the consequences of activating the E variant of ApoD in the brain upon oxidative stress? What impact does the E variant have on ApoD function? Is this an active mechanism to protect the brain from oxidative stress or just a marker of stress? Is this expression difference specific to paraquat or is the same response elicited using other forms of oxidative stress induction? Other phenomena were not investigated or discussed by the authors. For example, the restricted expression of the B variant in the brain suggests specialization of this variant and could be probed further.

In conclusion, the current manuscript is largely based on computational predictions that lack sufficient mechanistic confirmation of the regulation of ApoD expression and, thus, should not be accepted for publication.

Reviewer \#2: Evaluation of manuscript PONE-D-19-34292- Diez-Hermano et al 2020.

The manuscript by Diez-Hermano et al. report on the first analysis of the mouse ApoD 5'UTR region. The authors describe 5 novel ApoD variants which are differentially expressed in various tissues with variants B, D, and E showing CNS specificity. The authors further report two novel alternative promoters designated promoter alpha and beta that drive ApoD expression under control and paraquat-generated oxidative stress conditions.

The manuscript is well organized and easy to understand and presents interesting findings. However, there are minor issues that need to be addressed.

First, it is not possible to assess whether the statistical analysis been performed appropriately and rigorously as they are not described in the figure legends although the methods section states that "The tests used for each experiment are described in figure legends"

The reference list should be expanded. This research team has done extensive work on this subject in the past and it is thus understandable that many of the papers cited are from their group. However, this reviewer suggests adding key references on ApoD function in the brain such as He et al 2009; Kim et al 2009; Bhatia et al 2012, etc. The authors could also complement their list of references on ApoD involvement in Alzheimer's disease with Terrisse et al. J Neurochem. 1998; Belloir et al 2001; Desai et al 2005; Kalman et al. Neurol Res. 2000, etc.

Figure 2 describing the genomic structure of the mouse ApoD 5' UTR region and predicted mRNA transcripts variants would benefit from adding numbers both as presented in the tables (Fig.2 B and C) as well as in relation to the ORF (negative numbering). This would allow a better understanding of this region in relation to the promoter sequence previously published. The Fig. 2 legend should be extended to include information such as what the arrows in Fig. 2A correspond to.

Data and methods related to the differential expression of each 5'UTR variant are highly confusing and need major revision. The authors state that "RNA obtained from individual samples of the same tissue or experimental condition were pooled in equimolar amounts to be reversed transcribed." Perhaps they should expand on why such method was used instead of doing the RT on each individual sample. How can they be sure that the quantification is not biased by contaminating residual DNA or degradation sub-products? It is also confusing why the authors limit their investigation in brain to the cerebellum. Given the expression and importance of apoD in neurodegenerative conditions such as Alzheimer's and schizophrenia, it would be important to investigate the expression of the 5'UTR variants in other brain regions including the prefrontal cortex and hippocampus. Moreover, the primer combination used for each panel of Fig. 3 should be described either in the figure caption or in the methods section. Likewise, Table 1 should be revised. For example, primer pU1-F likely was used to amplify variants A, C and D but is assigned as used in "genomic PCR" only. Location (number) of the primers would be helpful. The difference between Fig. 3C and 3D must be explained. Were different primers used? In which case they should appear in Table 1. Lastly, since the authors speak of differential expression between tissues and conditions (lines 273-277; Fig. 3 C-F), the expression of a housekeeping gene should also be presented.

Regarding Fig. 7, a quantification of the increase in ApoD levels in IMA2.1 mouse astrocyte cells in control compared to OS conditions would be most informative. It would have also been interesting to include the full promoter region (represented in Fig. 6B) in the luciferase assays (Fig. 7) to better evaluate the extent of the effects that are specific to promoter alpha and beta under control and oxidative stress conditions.

In the discussion, the authors could further elaborate on the potential functional roles of the ApoD variants in control and in disease conditions, in particular oxidative stress conditions.
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Reviewer 1.

We are glad the Reviewer considers our in silico and experimental data and findings interesting. The Reviewer raises some general considerations on the completion of our study, which we are addressing below.

1\) "The computational methodologies used by the authors are not novel and are similar to those used in the author's previous publication..."

The bioinformatics analysis we have performed is not "novel" (methodologically speaking, as we have not developed any new algorithm to study the ApoD upstream gene regions), but we fail to see this kind of "novelty" as a requisite in the publication criteria of PLoS ONE. In addition, we have used different "computational methodologies" from those used to study the Lipocalin family in our previous publication to study ApoD promoter and to design experimental molecular biology tools.

2\) "...only the in vitro assays represent novel data that isn't readily available using online tools"

No wonder online tools can be "readily available" for everyone. However, only if we use them to uncover interesting predictions that can be tested experimentally, they do answer pertinent questions and contribute to Science advancement. This is the case for the interesting role of upstream UTRs in Lipocalins, and the reviewers judging those in fully silico data of our previous publication raised no concern. We believe this also applies to data included in the current manuscript: ApoD mRNA has been studied for a long time as if it were a single molecular species, without noticing that an alternative promoter and diverse 5'UTR versions could condition its expression. In this work we uncover predictions and test them experimentally, which is per se novel.

3\) "...the authors only probed embryonic whole brain and postnatal cerebellum of mice."

We think the reviewer misread the information mentioned in the Methods section and shown in Fig. 3, where we describe that our PCR experiments were also performed in cerebella of adults (6 months old) mice, both control and subjected to experimental oxidative stress.

4\) "Why is the cerebellum preferentially responsive to oxidative stress?

It was stated in line 277 of our manuscript, "Cerebellum was selected because of its reported expression of ApoD and its sensitivity to PQ \[19\]". We have added more information in the introduction section (lines 71-73) to help the reader better understand this choice from the beginning.

5\) "Why did the authors choose to examine their mechanism in cultured astrocytes versus other cell types in the brain...?"

We selected astrocyte cultures because it is one of the cell types expressing ApoD, where we have in depth knowledge about the role of ApoD in oxidative stress-dependent autocrine and paracrine protection. We explain in our manuscript (lines 435-438), that astrocytes "...show a low vesicular ApoD expression by immunolabeling under control condition, which increases when challenged with PQ (Figure 7A). This expression regulation is similar to that found in primary mouse astrocytes \[14,54\] and in the mouse brain upon similar oxidative stress conditions \[13,18\]."

6\) Statistical analysis.

In the revised version of the manuscript, we have included a more detailed explanation of the statistical tests used in our experiments.

In a more general sense, the Reviewer poses many interesting scientific questions not addressed in this work and concludes that much work must be done before we can publish it.

Although we agree that a more detailed study could reveal more mechanistic insights and details into ApoD function regulation, we would like the Reviewer to view our data from a different perspective.

Our laboratory works with model organisms (Drosophila and mouse) on the physiology of ApoD, but is not currently funded to study in depth gene transcriptional regulation or UTR secondary structures. However, after our last publication we decided to explore ApoD 5' UTR regions as a side project to our main grant objectives. We were able to demonstrate with standard molecular biology techniques that the predicted alternative 5' UTRs and a novel promoter do in fact exist, and could underlie differential expression in mouse tissues and in response to oxidative stress challenges. An interesting finding acknowledged by the Reviewer.

We agree that (as always in Science) more work can be done, and would actually love to answer all questions related to this interesting topic raised by the Reviewer. However, we are also aware that our current situation prevents to keep developing that project. That is why we believe it is important to disseminate our results to the scientific community interested in transcriptional regulation, instead of hiding them in our desks waiting for a major shift in our lab goals and funding opportunities. We sincerely predict that this work would spawn future research in the field of gene expression regulation.

 

Reviewer 2.

We are glad the Reviewer considers our findings interesting, and want to thank his/her careful and useful review. We address the Reviewer's concerns below and in the revised version of the manuscript.

1\) Statistical analysis description.

A detailed explanation of the statistical tests used in our experiments are included in the revised version of the manuscript.

2\) References missing in the general description of ApoD function in the brain.

Thanks for the suggestion. We have included the suggested references in the revised manuscript.

3\) Figure 2 data and design.

Thanks for the idea. We have reorganized and expand the figure panels and legends according to the Reviewer's suggestions.

4\) Data and methods related to the differential expression of each 5'UTR variant.

We have revised and rewritten this section taking into account the Reviewer's concerns. Below are our answers to these questions.

\- The primer combination used for each panel of Fig. 3 should be described.

We have included the primer combination used in each panel of the figure. Thanks for the suggestion.

\- The difference between Fig. 3C and 3D must be explained. Were different primers used?

Yes, those amplifications were carried out with different sets of primers. We had to use primers pU1F or pU2F to be able to separate variant A from C expression (several variants showed overlapping size). Variants B, D and E were easily identified with the primer pairs cited in the figure.

\- Table 1 should be revised.

We have done so, and the reviewer is right about primer pU1-F and its use in RT-PCR. We have checked and corrected the experimental use of all primers listed in the revised table.

\- RNA individual samples vs. Sample pools:

The Reviewer is right that two options can be used to account for biological and technical variabilities in experimental design. Biological variability can be evaluated by using individual samples for PCR amplifications, and technical variability would be evaluated by replicating amplifications. An alternative strategy could be to homogeneously mix equimolar amounts of RNA extracted from each individual tissue sample (obviously checking for RNA purity and integrity), thus rendering each tissue in a single pooled sample. Technical variability can be subsequently tested by experiment replicas.

We believe this approach fulfills an adequate assessment of both experimental variabilities present in biological research, and adds an economical aspect to consider (both in personal and reagent lab expenditure) for a scientist. In fact, we have been using this strategy in previous publications from our lab (Ganfornina et al 2005; Bajo et al., 2011; Sanchez et al., 2015) reporting expression data from microarray experiments, where resources and reagents costs are an issue to consider.

Moreover, the sample pooling strategy allows us to show 8 RTs (8 lanes) per PCR shown in figure 3B-F, instead of 42 RTs (and corresponding lanes) from individual sample experiments.

\- Quantification bias by contaminating residual DNA or degradation sub-products

RNA purity and integrity were monitored by 260/230 and 260/280 ratios measured with a spectrophotometer, and by agarose electrophoresis. Putatively contaminating DNA was avoided by DNAse treatment, and confirmed by RT(-) amplifications. These details have been added to the revised Methods section.

\- Why the authors limit their investigation in brain to the cerebellum?

As explained in the manuscript (line 277) the cerebellum was selected because of its reported expression of ApoD and its sensitivity to PQ \[18\]. We have added more information in the introduction section to help the reader understand this choice (lines 71-73). We agree that studying the role of 5' UTR regulation of ApoD in neurodegenerative conditions will be very interesting, but we chose to test for the relevance of 5' UTR variants in an experimental oxidative stress model well studied and reliably reproduced in our lab.

\- Differential expression between tissues and conditions and housekeeping gene.

We did not include a housekeeping gene in those semiquantitative PCR experiments because we wanted to compare the expression of the 5' UTR variants with that of ApoD CDS (shown in Fig. 3B), which in this case acts as the reference. We agree that when we refer to "differential expression of each 5' UTR variant" is not referred to a housekeeping gene, and therefore we have rephrased the paragraph in the manuscript stating the comparison with ApoD CDS in each tissue/condition.

In quantitative real-time PCR (Fig. 3G,H), though, we used Rpl18 as a housekeeping gene.

\- Quantification of the increase in ApoD levels in IMA2.1 mouse astrocyte cells in control compared to OS conditions.

We have performed the experiments suggested by the Reviewer, measuring ApoD expression by fluorescent immunocytochemistry and confirming the PQ-dependent overexpression. The new data was added as a new panel to Figure 7 (panel B).

\- To include full promoter region in the luciferase assays.

We agree with the reviewer that this should be something to pursue. However, we had trouble cloning the whole DNA piece into our vectors, and proceeded to study them as separate entities.

\- Further discussion on the potential roles of the ApoD variants in control and in disease conditions.

Although it is tempting to discuss the role of ApoD variants in human diseases, we feel our findings should be considered with caution, given their study in rodents. Thus, we have included a short statement in the revised version of the manuscript prompting the ApoD community to check the putative existence of 5' UTR variation for the human protein, and its role in human diseases.

###### 

Submitted filename: Response to reviewers PONE-D-19-34292.docx

###### 

Click here for additional data file.
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PLOS ONE

Dear Dr. Ganfornina,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 13 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Hiroyoshi Ariga

Academic Editor

PLOS ONE

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors did not adequately address the questions posed in our initial review of this paper and there are still too many unknowns to warrant publication of this manuscript at this time. The editorial decision was for major revision, but only minor edits were made to the manuscript and no additional data was provided. It should be noted that while the figures were reordered, the old figure titles remain, making the reading of the manuscript confusing.

The authors concede that the bioinformatic approach to this problem, which makes up the majority of the data presented herein, is not novel. Moreover, the in vitro assays provided in the paper are inadequate to definitively support the authors conclusions. While the authors state in their response that they have additional data in mice that might bolster their conclusions, they did not include those data. Without the addition of these or other in vivo data, this paper remains inadequate for publication.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0234857.r004

Author response to Decision Letter 1

3 Jun 2020

We are glad that our responses and changes made to the manuscript addressed all of Reviewer \#2 questions, and want to thank the reviewer for the improvements suggested for the revised version of our manuscript.

As for Reviewer \#1, we are also glad that he/she accepts our responses to previous questions on experimental details: e.g., why we chose cerebellum as a tissue type, and cultured astrocytes as a cell type to test the main question in this work, and that the bioinformatically predicted 5' UTR variants and alternative promoter do in fact exist and influence the Lipocalin ApoD gene expression. We are also glad the reviewer\'s positive marks to all editorial questions in the reviewer form.

Answering to some concerns:

1\) ..."only minor edits were made to the manuscript and no additional data was provided".

The revised version of the manuscript includes many changes addressing all of the constructive criticisms posed by Reviewer \#2. Moreover, panel B in figure 7 shows new data and analysis from immunocytochemical experiments proposed by Reviewer \#2. Thus, and again, we must correct Reviewer \#1 in his/her argument that "no additional data was provided". Moreover, we consider utterly unfair this statement, given the exceptional situation under which we have made those experiments in such difficult times of all our professional lives.

2\) ..."while the figures were reordered, the old figure titles remain, making the reading of the manuscript confusing."

As far as we can tell, we have not reordered any figure in this manuscript! We just included amendments suggested by Reviewer \#2 to some panels, and the already cited panel B in figure 7 showing the new experimental data required by Reviewer \#2. All those changes were incorporated in figure legends, and therefore we see no point in changing "figure titles". Finally, we do not understand that Reviewer \#1 now finds reading the manuscript "confusing" while answering "Yes" to comment 5.

3\) ..."concede that the bioinformatic approach to this problem, which makes up the majority of the data presented herein, is not novel".

While maintaining the argument that we do not see "novelty" as a requisite in the publication criteria of PLoS ONE, we see this comment as a rhetorically twisted reading of our response. To his/her initial consideration that "The computational methodologies used by the authors are not novel and are similar to those used in the author's previous publication ", we answered that we use in this manuscript different computational methodologies to study ApoD promoter and to design experimental molecular biology tools. So, the methodologies are not "similar". The only "concession" we made is that we did not develop any bioinformatic (novel) algorithm in our analysis. We are not bioinformaticians indeed! However, we must insist in that the bioinformatic approach we have used has discovered novel biological facts related to ApoD function.

4\) ... "While the authors state in their response that they have additional data in mice that might bolster their conclusions, they did not include those data."

We cannot find in our response a statement that we have "additional data in mice". We obviously did not include additional data performed in mice because we do not have them! The data we show in this manuscript are the data we have. We cannot provide "other in vivo data", as the reviewer requires, because we cannot collect them in the period of a manuscript revision.

10.1371/journal.pone.0234857.r005
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PONE-D-19-34292R2

Dear Dr. Ganfornina,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Hiroyoshi Ariga

Academic Editor

PLOS ONE

10.1371/journal.pone.0234857.r006
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PONE-D-19-34292R2

Control of the neuroprotective Lipocalin Apolipoprotein D expression by alternative promoter regions and differentially expressed mRNA 5' UTR variants

Dear Dr. Ganfornina:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Hiroyoshi Ariga

Academic Editor

PLOS ONE
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